In the first nine months of this year, Pfizer’s (PFE) Inlyta revenue grew ~12% YoY (year-over-year) to $226.0 million from $256.0 million. US Inlyta sales fell ~7% YoY to $88.0 million, while international Inlyta sales fell ~14% YoY to $138.0 million. Internationally, Inlyta operations declined ~16% YoY. In the third quarter, Inlyta revenue fell ~15% YoY to $71.0 million, with US and international Inlyta sales falling ~10% and ~18% YoY to $27.0 million and $44.0 million, respectively.
In September, the FDA approved Pfizer’s Vizimpro as a first-line treatment of metastatic non-small cell lung cancer with an exon-19 deletion or exon-21-L858R substitution. The ARCHER 1050 trial demonstrated Vizimpro’s safety and efficacy.
Also, in October, the FDA approved Pfizer’s Talzenna (talazoparib) for treating adults with deleterious germline BRCA-mutated human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer. The new FDA approvals are set to strengthen Pfizer’s oncology portfolio, which could significantly boost the company’s revenue growth and the iShares US Pharmaceuticals ETF (IHE), of which Pfizer comprises ~10.21%.